Product
TF0023
Aliases
Active drug, IP, Active drug
2 clinical trials
2 indications
Indication
strokeIndication
COVID-19 PneumoniaClinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study to Evaluate the Efficacy and Safety of TF0023 Spray Versus Placebo in Functional Improvement of Patients With Ischemic StrokesStatus: , Estimated PCD: 2024-10-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind (Within Dose), Placebo-controlled, Parallel-group, and Dose-range-finding to Evaluate the Efficacy and Safety in Treatments for COVID-19 in Hospitalized AdultsStatus: Terminated, Estimated PCD: 2023-02-03